It reported that overall mortality and CV events were significantly reduced in patients treated with anti-TNFs with relative risk (RR) = 0.60 [95% CI 0.38–0.94] and RR = 0.62 [95% CI 0.44–0.88], respectively, with no effect on the risk of neoplasm but a significant increase in infections during anti-TNF treatment (RR = 1.48 [1.18–1.85]) compared to those who were treated with classical DMARDs [123]. This evidence concerns the gene TNF and infection.